View of Delayed-onset vitiligo in metastatic HR+/HER2– breast cancer during long-term ribociclib therapy.

Return to Issue Details Delayed-onset vitiligo in metastatic HR+/HER2– breast cancer during long-term ribociclib therapy. Download Download PDF